Pharmacotherapy of Autism and related disorders

Kelly Blankenship, Craig A. Erickson, Christopher J. McDougle

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Public awareness of pervasive developmental disorders (PDDs), including autistic disorder (autism), has been increasing. In parallel, results from research directed toward pharmacologic treatment of interfering symptoms associated with PDDs has escalated. This review will focus on controlled drug studies performed to treat the interfering symptoms of PDDs. These include hyperactivity/inattention, repetitive and stereotypic behavior, irritability (aggression, self-injury, severe tantrums) and core social impairment. A priority is placed on randomized, placebo-controlled trials when available. The side effects of the medications in this population are also discussed.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalPsychiatric Annals
Volume40
Issue number4
DOIs
StatePublished - Apr 1 2010

Fingerprint

Autistic Disorder
Drug Therapy
Aggression
Randomized Controlled Trials
Placebos
Wounds and Injuries
Research
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Blankenship, K., Erickson, C. A., & McDougle, C. J. (2010). Pharmacotherapy of Autism and related disorders. Psychiatric Annals, 40(4), 203-209. https://doi.org/10.3928/00485713-20100330-06

Pharmacotherapy of Autism and related disorders. / Blankenship, Kelly; Erickson, Craig A.; McDougle, Christopher J.

In: Psychiatric Annals, Vol. 40, No. 4, 01.04.2010, p. 203-209.

Research output: Contribution to journalArticle

Blankenship, K, Erickson, CA & McDougle, CJ 2010, 'Pharmacotherapy of Autism and related disorders', Psychiatric Annals, vol. 40, no. 4, pp. 203-209. https://doi.org/10.3928/00485713-20100330-06
Blankenship, Kelly ; Erickson, Craig A. ; McDougle, Christopher J. / Pharmacotherapy of Autism and related disorders. In: Psychiatric Annals. 2010 ; Vol. 40, No. 4. pp. 203-209.
@article{3bac5e5b713745c192f213fec4032de7,
title = "Pharmacotherapy of Autism and related disorders",
abstract = "Public awareness of pervasive developmental disorders (PDDs), including autistic disorder (autism), has been increasing. In parallel, results from research directed toward pharmacologic treatment of interfering symptoms associated with PDDs has escalated. This review will focus on controlled drug studies performed to treat the interfering symptoms of PDDs. These include hyperactivity/inattention, repetitive and stereotypic behavior, irritability (aggression, self-injury, severe tantrums) and core social impairment. A priority is placed on randomized, placebo-controlled trials when available. The side effects of the medications in this population are also discussed.",
author = "Kelly Blankenship and Erickson, {Craig A.} and McDougle, {Christopher J.}",
year = "2010",
month = "4",
day = "1",
doi = "10.3928/00485713-20100330-06",
language = "English (US)",
volume = "40",
pages = "203--209",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy of Autism and related disorders

AU - Blankenship, Kelly

AU - Erickson, Craig A.

AU - McDougle, Christopher J.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Public awareness of pervasive developmental disorders (PDDs), including autistic disorder (autism), has been increasing. In parallel, results from research directed toward pharmacologic treatment of interfering symptoms associated with PDDs has escalated. This review will focus on controlled drug studies performed to treat the interfering symptoms of PDDs. These include hyperactivity/inattention, repetitive and stereotypic behavior, irritability (aggression, self-injury, severe tantrums) and core social impairment. A priority is placed on randomized, placebo-controlled trials when available. The side effects of the medications in this population are also discussed.

AB - Public awareness of pervasive developmental disorders (PDDs), including autistic disorder (autism), has been increasing. In parallel, results from research directed toward pharmacologic treatment of interfering symptoms associated with PDDs has escalated. This review will focus on controlled drug studies performed to treat the interfering symptoms of PDDs. These include hyperactivity/inattention, repetitive and stereotypic behavior, irritability (aggression, self-injury, severe tantrums) and core social impairment. A priority is placed on randomized, placebo-controlled trials when available. The side effects of the medications in this population are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=77951729952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951729952&partnerID=8YFLogxK

U2 - 10.3928/00485713-20100330-06

DO - 10.3928/00485713-20100330-06

M3 - Article

AN - SCOPUS:77951729952

VL - 40

SP - 203

EP - 209

JO - Psychiatric Annals

JF - Psychiatric Annals

SN - 0048-5713

IS - 4

ER -